Hayman Capital's Bass: J&J vaccine halt isn't an event for the market

U.S. stock futures dropped in a sudden move after the U.S. Food and Drug Administration said it’s recommending a pause in the Johnson & Johnson Covid vaccine after reported cases of blood clotting. Kyle Bass, Hayman Capital Management chief investment officer, offers his reaction to the news and how he thinks it will affect the market.
Tue, Apr 13 20219:47 AM EDT